Comparative Pharmacology
Head-to-head clinical analysis: KENGREAL versus PYRIDAMAL 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENGREAL versus PYRIDAMAL 100.
KENGREAL vs PYRIDAMAL 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cangrelor is a reversible, direct-acting P2Y12 platelet receptor antagonist that inhibits ADP-mediated platelet activation and aggregation.
Dipyridamole inhibits platelet phosphodiesterase, reducing platelet aggregation; also inhibits adenosine deaminase and increases extracellular adenosine, leading to vasodilation.
10 mcg/kg intravenous bolus over 1-2 minutes, followed by 0.1 mcg/kg/min continuous intravenous infusion for 2-4 hours.
100 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3–6 minutes (mean 3.3 minutes), allowing rapid recovery of platelet function within 60 minutes of infusion cessation.
Terminal half-life 10-12 hours; clinical context: steady state achieved in 3-5 days; renal impairment prolongs half-life
Cangrelor is metabolized via rapid dephosphorylation to its major metabolite, a nucleoside, which is further degraded; approximately 58% of the dose is excreted in urine as unchanged cangrelor and metabolites, with <35% in feces.
Renal: 50-70% unchanged; biliary/fecal: 20-30% as metabolites; total renal elimination ~85%
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent